Using data from NIH’s database of Genotypes and Phenotypes (dbGaP) and NCI’s Proteomic Data Commons (PDC), researchers studied resistance to chemotherapy in triple negative breast cancer.

Their proteogenomic analysis of triple negative breast tumors revealed a complex landscape of significant chemotherapy response associations with lack of pathological response, carboplatin-selective resistance, poor prognosis, and chromosomal instability. To come to this conclusion, researchers cross-examined genomic data from dbGaP and mass spectrometry proteomic data from PDC generated using a microscaled approach.

This study shows how integrated multi-omic data combined with clinical research can further our understanding of cancer. Additional studies are underway to discover ways to better predict the most effective treatments for patients in a clinical setting.

The researchers published the study (funded by NCI’s Clinical Proteomics Tumor Analysis Consortium) in Cancer Discovery.

Read more about the study on the Office of Cancer Clinical Proteomics Research website.